Evidence map›Paper›PMID 41594702›Full record

ArticleBiomolecules2026

In Silico Ligand-Based Screening of PDB Database for Searching Unique Motifs Against SARS-CoV-2.

Andrey V Machulin, Juliya V Badaeva, Sergei Y Grishin, Evgeniya I Deryusheva, Oxana V Galzitskaya

Abstract read
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrey V MachulinG.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center Pushchino Scientific Center for Biological Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0002-4859-7219
Juliya V BadaevaMoscow Timiryazev Agricultural Academy, Russian State Agrarian University, 127434 Moscow, Russia.
Sergei Y GrishinInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0001-7373-9808
Evgeniya I DeryushevaInstitute for Biological Instrumentation, Federal Research Center Pushchino Scientific Center for Biological Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0002-6213-2784
Oxana V GalzitskayaInstitute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.ORCID 0000-0002-3962-1520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2, the virus responsible for coronavirus disease COVID-19, is a highly transmissible pathogen that has caused substantial global morbidity and mortality. The ongoing COVID-19 pandemic caused by this virus has had a significant impact on public health and the global economy. One approach to combating COVID-19 is the development of broadly neutralizing antibodies for prevention and treatment. In this work, we performed an in silico ligand-based screening of the PDB database to search for unique anti-SARS-CoV-2 motifs. The collected data were organized and presented in a classified SARS-CoV-2 Ligands Database, categorized based on the number of ligands and structural components of the spike glycoprotein. The database contains 1797 entries related to the structures of the spike glycoprotein (UniProt ID: P0DTC2), including both full-length molecules and their fragments (individual domains and their combinations) with various ligands, such as angiotensin-converting enzyme II and antibodies. The database's capabilities allow users to explore various datasets according to the research objectives. To search for motifs in the receptor-binding domain (RBD) most frequently involved in antibody binding sites, antibodies were classified into four classes according to their location on the RBD; for each class, special binding motifs are revealed. In the RBD binding sites, specific tyrosine-containing motifs were found. Data obtained may help speed up the creation of new antibody-based therapies, and guide the rational design of next-generation vaccines.

Indexed as

Antiviral AgentsDatabases, ProteinSpike Glycoprotein, CoronavirusAmino Acid MotifsAngiotensin-Converting Enzyme 2Binding SitesComputer SimulationCOVID-19HumansLigandsPandemicsPeptidyl-Dipeptidase ASARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsLigandsPeptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2angiotensin converting enzyme II (ACE2)binding motifsPDB databasereceptor-binding domain (RBD)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)therapeutic antibodies

Identifiers

PMID41594702
PMCPMC12839228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.